Clinical responses in patients with p53 mutations, deletions, or both were noted in 6 (40%) of 15 versus 4 (19%) of 21 of patients without. The median response duration for this subset of patients was 8 months (range, 3-17 months). These data suggest that alemtuzumab may be an effective therapy for patients with CLL with p53 mutations or deletions...Similar to the results reported in that single case report, several patients included in our series had durable remissions that ranged from 3 to 17 months with 3 having complete eradication of the del(17)(p13.1) clone in the bone marrow after therapy.